NIKKEI 225
38,054.13 -502.74 (-1.30%) HANG SENG
18,230.19 -246.82 (-1.34%) CRUDE OIL
77.72 -1.51 (-1.91%) GOLD FUTURES
2,366.20 +2.10 (+0.09%) DOW
38,151.31 -290.23 (-0.75%) Bitcoin GBP
54,359.27 +1,400.63 (+2.64%)
Spyre Therapeutics, Inc. (SYRE)
| Previous close | 32.06 |
| Open | 32.28 |
| Bid | 33.72 x 100 |
| Ask | 34.03 x 100 |
| Day's range | 32.07 - 34.19 |
| 52-week range | 2.65 - 47.97 |
| Volume | |
| Avg. volume | 444,738 |
| Market cap | 1.365B |
| Beta (5Y monthly) | 2.93 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference
Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment of Inflammatory Bowel Disease ("IBD"), today announced that management will participate in a fireside chat and investor meetings at the Jefferies Global Healthcare Conference. Details of the fireside are as follows:
- PR Newswire
Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment of Inflammatory Bowel Disease ("IBD"), today announced the appointment of Sandra Milligan, M.D., J.D., President of Aspira Women's Health, to its Board of Directors.
- PR Newswire
Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment of inflammatory bowel disease ("IBD"), today announced its first quarter 2024 financial results and provided program and corporate updates.
